PHK
CTMX icon

Point72 Hong Kong’s CytomX Therapeutics CTMX Stock Holding History

Point72 Hong Kong’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,600
Closed -$10K – 1868
2020
Q4 		$10K Buy
1,600
+1,235
+338% +$8.82K ﹤0.01% 1539
2020
Q3 		$2K Buy
+365
New +$2.71K ﹤0.01% 1117
2020
Q1 		– Sell
-1,135
Closed -$9K – 1030
2019
Q4 		$9K Buy
+1,135
New +$7.66K ﹤0.01% 987
2018
Q4 		– Sell
-1,347
Closed -$25K – 949
2018
Q3 		$25K Buy
1,347
+1,300
+2,766% +$29.6K 0.01% 567
2018
Q2 		$1K Buy
47
+33
+236% +$843 ﹤0.01% 820
2018
Q1 		$0 Buy
+14
New +$400 ﹤0.01% 947

Other funds holding CTMX

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Point72 Hong Kong's CTMX Position: Q1 2021 in Review

Point72 Hong Kong sold out of CytomX Therapeutics (CTMX) in Q1 2021, closing a stake of 1,600 shares — an estimated $10K sold.

Point72 Hong Kong first reported a position in CTMX in Q1 2018 and held it in 6 quarters. The position peaked at $25K in Q3 2018. 126 funds tracked by Wall St. Rank hold CTMX as of Q1 2021.

  • Point72 Hong Kong reported no remaining CytomX Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Point72 Hong Kong sold 1,600 CytomX Therapeutics shares in Q1 2021, an estimated $10K.
  • Point72 Hong Kong first reported a position in CytomX Therapeutics in Q1 2018 and held it in 6 quarters.
  • Point72 Hong Kong's CytomX Therapeutics position peaked at $25K in Q3 2018.
  • 126 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2021.

Based on Point72 Hong Kong's 13F filing for Q1 2021, filed 17 May 2021.